GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovaCare Inc (OTCPK:RCAR) » Definitions » Inventory-to-Revenue

RenovaCare (RenovaCare) Inventory-to-Revenue

: 0.00 (As of Sep. 2022)
View and export this data going back to . Start your Free Trial

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. RenovaCare's Average Total Inventories for the quarter that ended in Sep. 2022 was $0.00 Mil. RenovaCare's Revenue for the three months ended in Sep. 2022 was $0.00 Mil.

RenovaCare's Inventory-to-Revenue for the quarter that ended in Sep. 2022 stayed the same from Jun. 2022 (0.00) to Jun. 2022 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.


RenovaCare Inventory-to-Revenue Historical Data

The historical data trend for RenovaCare's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovaCare Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Inventory-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

RenovaCare Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Inventory-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, RenovaCare's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RenovaCare Inventory-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, RenovaCare's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where RenovaCare's Inventory-to-Revenue falls into.



RenovaCare Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

RenovaCare's Inventory-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Inventory-to-Revenue (A: Dec. 2021 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2020 ) + Total Inventories (A: Dec. 2021 )) / count ) / Revenue (A: Dec. 2021 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=N/A

RenovaCare's Inventory-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

Inventory-to-Revenue (Q: Sep. 2022 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Jun. 2022 ) + Total Inventories (Q: Sep. 2022 )) / count ) / Revenue (Q: Sep. 2022 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RenovaCare  (OTCPK:RCAR) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

RenovaCare's Days Inventory for the three months ended in Sep. 2022 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2022 )/Cost of Goods Sold (Q: Sep. 2022 )*Days in Period
=0/0*365 / 4
=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

RenovaCare's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2022 ) / Average Total Inventories (Q: Sep. 2022 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RenovaCare Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of RenovaCare's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


RenovaCare (RenovaCare) Business Description

Traded in Other Exchanges
N/A
Address
9375 East Shea Boulvard, Suite 107-A, Scottsdale, AZ, USA, 85260
RenovaCare Inc is a biotechnology company focusing on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company's initial products under development target skin. It offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). RenovaCare is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Geographically all the activities are functioned through the region of United States.
Executives
Patsy Trisler officer: Vice President 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Thomas Bold officer: President & CEO 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Joseph Sierchio director 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Kenneth Kirkland director 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Rhonda Beth Rosen director, officer: President & CEO 43 DICKINSON ROAD, BASKING RIDGE NJ 07920
1420525 Alberta Ltd. 10 percent owner 1628 WEST 1ST AVENUE, SUITE 216, VANCOUVER A1 V6J1G1
David E Jenkins director 406 NORTH HERMOSA DRIVE, PALM SPRINGS CA 92262
Antonino G Cacace director, officer: President CRUD-Y-GWYNT, CASWELL BAY, SWANSEA X0 SA3 3BU
Jeet Sidhu director 5667 SUNRISE CRESCENT WEST, SURREY, BC A1 V3S 7M4
Derek Cooper officer: President/ CEO
Frank J Fabio officer: CFO/Sec.(Resigned 1/9/2009) 670 BROADWAY, MASSAPEQUA NY 11758
Christian F Hudson director 33 CHURCHILL ROAD, TENAFLY NJ 07670
Harmel S Rayat director, 10 percent owner 700 - 688 WEST HASTINGS STREET, VANCOUVER A1 V6B 1P1
Stanley Wong officer: President/CEO
Terri Dumoulin director, officer: Secretary/Treasurer

RenovaCare (RenovaCare) Headlines

From GuruFocus

RenovaCare Announces Management Changes

By GuruFocusNews GuruFocusNews 03-24-2022

RenovaCare Announces Termination of StemCell Systems R&D Agreement

By GuruFocusNews GuruFocusNews 05-03-2022